Lipid-lowering effects of statins: a comparative review.
The pharmacological regulation of lipid metabolism in patients with dyslipidaemia is unequivocally associated with significant reductions in risk for cardiovascular morbidity and mortality. There is strong clinical trial data to support of the use of statin therapies in the settings of both primary and secondary prevention. This paper addresses: i) the mechanisms of action of antilipidaemic medications; ii) dosing regimens and the pharmacokinetic differences among drugs of the same class; iii) risk for drug interactions; and iv) reviews the clinical trial evidence used to support the use of particular antilipidaemic medications in specific physiological settings.
Davidson
Michael H
MH
Radiant Research, Chicago, IL, USA. michaeldavidson@radiantresearch.com
Robinson
Jennifer G
JG
D051544:Cytochrome P-450 CYP3A / Q000145:classification / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism; D007527:Isoenzymes / Q000145:classification / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D016896:Treatment Outcome
D065692:Cytochrome P-450 CYP3A Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007527:Isoenzymes; D051544:Cytochrome P-450 CYP3A